Trump wants to put tariffs on prescription drugs. Experts warn it could backfire.
Published On Feb 8, 2025, 8:10 AM
Donald Trump is threatening to impose tariffs on foreign-made prescription drugs, aiming to encourage drug manufacturers to relocate production to the U.S. While the intention is to bolster domestic manufacturing, experts warn that these tariffs could lead to increased drug prices and shortages, particularly of generic medications. Nearly two-thirds of generic drugs are produced overseas, and tariffs could exacerbate existing supply issues and overall healthcare costs without significantly increasing domestic production. Experts suggest that while some patented drugs might see a strategic shift due to tariffs, the impact on generics could be negative, prompting manufacturers to exit the market rather than absorb additional costs.
Stock Forecasts
PFE
Negative
The potential tariffs on prescription drugs could lead to increased costs for healthcare providers and patients, particularly impacting the pricing of generic drugs. This could inversely affect customarily stable drug prices and create supply shortages. The pharmaceutical sector could face downward pressure if drug manufacturers seek to increase prices or exit the market, further impacting investors.
Related News
Leaving the W.H.O. Could Hurt Americans on a Range of Health Matters
Jan 29, 2025, 5:01 AM
President Trump’s decision to pull out of the international health agency could deprive the United States of crucial scientific data and lessen the country’s influence in setting a global health agenda.
Sacklers Up Their Offer to Settle Purdue Opioids Cases, With a New Condition
Jan 23, 2025, 12:04 PM
A group of 15 states have reached a tentative new deal that would require them to set aside hundreds of millions of dollars from the settlement in a legal-defense fund for the family.
Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report
Jan 6, 2025, 5:01 AM
But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who benefited said the improvement didn’t last.